arrow
L

L. Chaigneau

centre hospitalier universitaire de besancon
H指数:34
被引数:4,556

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics and outcome of intra-abdominal desmoid-type fibromatosis

腹内型硬纤维瘤的特征和预后

2026-05-190
PRE
Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France

法国一个大型基于临床队列的转移性乳腺癌患者中生殖系BRCA1/2突变

Cancers
IF4.4
2026-03-120
OAAI
Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

依维莫司在激素受体阳性、HER2阴性、转移性乳腺癌患者中的疗效,该患者群体曾接受过CDK4/6抑制剂预治疗

2025-12-240
OAAI
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

瑞戈非尼作为一线多柔比星类化疗后的维持疗法在进展期非脂肪源性软组织肉瘤患者中的应用:一项双盲随机试验☆

2025-04-080
PRE
Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC

神经纤维瘤病1型(NF1)相关胃肠道间质瘤(GISTs)的临床描述及预后评分的开发:一项来自NETSARC的回顾性研究

2025-03-010
OAAI
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6年与3年伊马替尼辅助治疗局部GIST复发风险高的患者的随机研究

2024-12-016
OAAI
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
2024-09-010
PRE
EREMISS trial: A double-blind placebo (PBO)- controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)

EREMISS试验:一项双盲安慰剂(PBO)对照的随机试验,评估regorafenib(REGO)作为维持疗法在经过一线多柔比星为基础的化疗后的晚期软组织肉瘤(ASTS)患者(pts)中的疗效/安全性。

2024-09-010
PRE
Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC plus network

辅助伊马替尼对神经纤维瘤病1型(NF1)相关GIST复发的影响:基于法国NETSARC plus网络RECKGIST队列的分析

2024-09-010
PRE
Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC plus network

神经纤维瘤病1型(NF1)相关GIST的RECKGIST队列的临床描述及预后评分的制定:一项来自法国NETSARC plus网络的回顾性研究

2024-09-010
PRE
Improved nationwide survival of sarcoma patients with a network of reference centers
2024-04-019
OA
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
CANCER
IF5.1
2024-03-122
OAAI
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
2023-10-0111
OA
A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study
2023-05-172
OAAI
Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

青少年和年轻成人肉瘤患者的管理和结果: 来自法国全国数据库NETSARC的结果

2023-01-209
OAAI
Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group
2021-11-050
OA